Terumo (4543) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
1 Jul, 2026Executive summary
Sales revenue for fiscal 2024 surpassed JPY 1 trillion for the first time, growing 12–12.4% year-over-year, driven by global demand, especially in the US and Americas, and a weaker yen.
Operating profit reached a record high for the fourth consecutive year, despite one-time expenses of JPY 24.2 billion related to restructuring, impairment, and litigation.
Net income and free cash flow hit record highs, with free cash flow nearly doubling to JPY 128.3 billion.
All business segments and regions posted double-digit growth, even excluding FX effects.
Strategic focus remains on innovation, global expansion, and strengthening the CDMO business, including a major European acquisition.
Financial highlights
Sales revenue: JPY 1,036.2 billion, up 12–12.4% year-over-year.
Operating profit: JPY 157.7 billion; adjusted operating profit: JPY 203.4 billion (+29.8% year-over-year), both record highs.
Adjusted operating profit margin improved to 19.6% (+2.6 percentage points year-over-year).
Free cash flow increased by JPY 63.5 billion year-over-year, reaching JPY 128.3 billion.
Gross margin improved to 54.1% from 52.0% year-over-year.
Outlook and guidance
FY2025/2026 revenue guidance: JPY 1,050.0 billion (+1–7% year-over-year, +7% FX neutral); adjusted operating profit forecast: JPY 214.0 billion (+5.2%).
Operating profit expected to grow 24–32% due to business expansion and absence of prior one-time expenses.
Dividend per share to increase from JPY 26 to JPY 31–30, with a payout ratio of 31–33%.
US/China reciprocal tariffs could impact profit by up to JPY 17 billion, not yet factored into guidance.
ROIC and ROE projected to rise to 8.8% and 10.1%, respectively.
Latest events from Terumo
- FY26 targets robust growth via innovation in C&V, CDMO, Africa, and organ transplant solutions.4543
Investor Day 202611 Jun 2026 - Record revenue and profit, with double-digit growth expected to continue in FY2026/2027.4543
Q4 202620 May 2026 - Record revenue and profit growth driven by global demand and strategic acquisitions.4543
Q3 202612 Apr 2026 - Record revenue and profit growth, with double-digit gains and improved margins.4543
Q1 20252 Feb 2026 - Record sales and profit surge drive raised guidance, innovation, and share split.4543
Q2 202516 Jan 2026 - Innovation, M&A, and new launches fuel global growth and margin expansion.4543
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Record revenue and profit growth driven by global demand, pricing, and FX gains.4543
Q3 20258 Jan 2026 - $1.5B acquisition accelerates entry into organ transplantation, driving growth and innovation.4543
M&A Announcement23 Nov 2025 - Record revenue and profit growth, upward guidance, but lower OP due to acquisition costs.4543
Q2 202614 Nov 2025